.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Fish and Richardson
Dow
Express Scripts
Cantor Fitzgerald
Teva
Accenture
Federal Trade Commission
Chubb
US Department of Justice

Generated: September 23, 2017

DrugPatentWatch Database Preview

Moxifloxacin hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for moxifloxacin hydrochloride and what is the scope of moxifloxacin hydrochloride freedom to operate?

Moxifloxacin hydrochloride
is the generic ingredient in six branded drugs marketed by Watson Labs Inc, Novartis Pharms Corp, Aurobindo Pharma Ltd, Mylan Labs Ltd, Mylan Pharms Inc, Teva Pharms Usa, Dr Reddys Labs Ltd, Crossmedika Sa, Torrent Pharms Ltd, Lupin Ltd, Fresenius Kabi Usa, Bayer Hlthcare, Apotex Inc, and Novel Labs Inc, and is included in seventeen NDAs. There are seven patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Moxifloxacin hydrochloride has one hundred and sixty-one patent family members in forty-seven countries.

There are eighteen drug master file entries for moxifloxacin hydrochloride. Twenty-eight suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for Generic Name: moxifloxacin hydrochloride

Tradenames:6
Patents:7
Applicants:14
NDAs:17
Drug Master File Entries: see list18
Suppliers / Packagers: see list28
Bulk Api Vendors: see list58
Clinical Trials: see list2,547
Patent Applications: see list1,067
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:moxifloxacin hydrochloride at DailyMed

Pharmacology for Ingredient: moxifloxacin hydrochloride

Ingredient-typeQuinolones
Drug ClassQuinolone Antimicrobial

Tentative approvals for MOXIFLOXACIN HYDROCHLORIDE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe0.5%SOLUTION; OPHTHALMIC
► Subscribe► Subscribe0.5%SOLUTION; OPHTHALMIC
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare
AVELOX
moxifloxacin hydrochloride
TABLET;ORAL021085-001Dec 10, 1999ABRXYesYes► Subscribe► Subscribe ► Subscribe
Bayer Hlthcare
AVELOX
moxifloxacin hydrochloride
TABLET;ORAL021085-001Dec 10, 1999ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Novartis Pharms Corp
MOXEZA
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC022428-001Nov 19, 2010AT2RXYesYes► Subscribe► SubscribeY ► Subscribe
Novartis Pharms Corp
VIGAMOX
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC021598-001Apr 15, 2003AT1RXYesYes► Subscribe► SubscribeY► Subscribe
Bayer Hlthcare
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER
moxifloxacin hydrochloride
SOLUTION;IV (INFUSION)021277-001Nov 30, 2001APRXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
MOXEZA
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC022428-001Nov 19, 2010AT2RXYesYes► Subscribe► SubscribeY► Subscribe
Aurobindo Pharma Ltd
MOXIFLOXACIN HYDROCHLORIDE
moxifloxacin hydrochloride
TABLET;ORAL202632-001Mar 4, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Fresenius Kabi Usa
MOXIFLOXACIN HYDROCHLORIDE
moxifloxacin hydrochloride
SOLUTION;IV (INFUSION)205572-001Apr 3, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
MOXIFLOXACIN HYDROCHLORIDE
moxifloxacin hydrochloride
TABLET;ORAL204635-001Aug 31, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex Inc
MOXIFLOXACIN HYDROCHLORIDE
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC090080-001Jun 30, 2017AT1RXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: moxifloxacin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER
moxifloxacin hydrochloride
SOLUTION;IV (INFUSION)021277-001Nov 30, 2001► Subscribe► Subscribe
Bayer Hlthcare
AVELOX
moxifloxacin hydrochloride
TABLET;ORAL021085-001Dec 10, 1999► Subscribe► Subscribe
Novartis Pharms Corp
MOXEZA
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC022428-001Nov 19, 2010► Subscribe► Subscribe
Bayer Hlthcare
AVELOX
moxifloxacin hydrochloride
TABLET;ORAL021085-001Dec 10, 1999► Subscribe► Subscribe
Novartis Pharms Corp
VIGAMOX
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC021598-001Apr 15, 2003► Subscribe► Subscribe
Novartis Pharms Corp
VIGAMOX
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC021598-001Apr 15, 2003► Subscribe► Subscribe
Novartis Pharms Corp
VIGAMOX
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC021598-001Apr 15, 2003► Subscribe► Subscribe
Bayer Hlthcare
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER
moxifloxacin hydrochloride
SOLUTION;IV (INFUSION)021277-001Nov 30, 2001► Subscribe► Subscribe
Bayer Hlthcare
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER
moxifloxacin hydrochloride
SOLUTION;IV (INFUSION)021277-001Nov 30, 2001► Subscribe► Subscribe
Novartis Pharms Corp
MOXEZA
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC022428-001Nov 19, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: moxifloxacin hydrochloride

Country Document Number Estimated Expiration
European Patent Office0780390► Subscribe
Hungary229065► Subscribe
Russian Federation2494727► Subscribe
CroatiaP20020198► Subscribe
Bulgaria106366► Subscribe
Russian Federation2260429► Subscribe
Slovakia1682002► Subscribe
Uruguay31880► Subscribe
South Africa200103141► Subscribe
Norway320743► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: MOXIFLOXACIN HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
01C/030Belgium► SubscribePRODUCT NAME: MOXIFLOXACINE CHLORHYDRATE (CORRESPONDANT A MOXIFLOXACINE); NATL. REGISTRATION NO/DATE: 187 IS 328 F 3 20010507; FIRST REGISTRATION: DE 45263.00.00 19990621
2004012,C0780390Lithuania► SubscribePRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-1,4-DIHIDRO-8-METOKSI-7-((4AS, 7AS)-OKTAHIDRO-6H-PIROLO(3,4-B)PIRIDIN-6-IL)-4-OKSO-3-CHINOLINKARBOKSIRUGSTIES HIDROCHLORIDAS); REGISTRATION NO/DATE: 04/8383/3 20040309
2004012Lithuania► SubscribePRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-__ 1,4-DIHIDRO-8-METOKSI-7-[(4AS, 7AS)-OKTAHIDRO-6H-PIROLO[3,4-B]PIRIDIN_-6-IL]-4-OKSO-3-CHINOLINKARBOKSIRûGðTIES HIDROCHLORIDAS)
C/GB03/034United Kingdom► SubscribePRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313
00111Netherlands► SubscribePRODUCT NAME: MOXIFLOXACINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER MOXIFLOXACINEHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 28118 RVG 28119 20021017; FIRST REGISTRATION: DE 45263.00.00 19990621
/2000Austria► SubscribePRODUCT NAME: MOXIFLOXACIN, DESSEN PHARMAZEUTISCH VERWENDBARE HYDRATE UND SAEUREADDITIONSSALZE, DESSEN ALKALI-ERDALKALI-SILBER- UND GUANIDINIUMSALZE, SOWIE DESSEN C1 - C4 ALKYL- ODER; NAT. REGISTRATION NO/DATE: 1-23494, 1-23495, 1-23496 20000215; FIRST REGISTRATION: DE 45263.00.00 19990621
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Daiichi Sankyo
Johnson and Johnson
QuintilesIMS
Colorcon
UBS
Mallinckrodt
Medtronic
Healthtrust
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot